Thrombin antiplatelet agent

Himbacine (80) Alkaloid SCH 530348 (TRA) (81) Cardiovascular diseases (antiplatelet agent) Thrombin receptor antagonist Phase III (acute coronary syndromes) Schering-Plough 623-626... [Pg.65]

Several newer approaches to antiplatelet drug development have been recently discovered (122). These include inhibitions of the vWf/GPIb interaction, the platelet/collagen interaction, and the thrombin-induced platelet activation. Other approaches to platelet inhibition include the use of serotonin antagonists (because serotonin induces platelet aggregation), nitric oxide-donating antiplatelet agents, phosphodiesterase inhibitors, and inducers of adenyl cyclase. [Pg.1243]

The pharmacological treatment options for ACS include agents that either reduce oxygen demand (beta blockers) or increase oxygen supply (nitrates, potassium channel activators, calcium channel blockers) to the heart and antiplatelet (aspirin, ADP-receptor antagonists, GPIIb/llla receptor blockers) and antithrombin therapy (unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors) (10). [Pg.119]

Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects 06JMC5389. [Pg.42]

Chackalamannil, S. (2006) Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. Journal of Medicinal Chemistry, 49 (18), 5389-5403. [Pg.574]